Your current location：Home > News > Industry News

Sutro biopharma released data on the safety and potential anticancer activity of stro-002

Time：2019-10-30 11:32:16  Source：  Author：

 

 Today, Sutro biopharma, Inc.in San Francisco, California, USA, released data on the safety and potential anticancer activity of stro-002, an anti folate alpha receptor antibody drug conjugate (ADC), on a pre clinical xenotransplantation (PDX) model derived from patients with endometrial cancer.

 
 
 
The ongoing phase I trial is an open label, multicenter, incremental dose study to determine stro-002mtd, evaluate the safety, tolerability, and preliminary antitumor activity of stro-002, and find the recommended phase II dose.
 
 
 
So far, the company has applied stro-002 to 13 patients in phase I study, but has not found the maximum tolerable dose (MTD).
 
 
 
Two of the patients received 6 mg / kg of the drug and showed normal performance during the DLT observation period.
 
 
 
The company will increase its usage in the future. So far, there is no DLT and infusion response in these patients who have received a lot of treatment. Preliminary evidence of antitumor activity was observed in patients with partial response confirmed by the RECIST 1.1 standard.
Last Next

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL：+86-21-33585366(DDT)、34666753 FAX：+86-21-34979012
E-mail：info@shyrchem.com ADD：1885 Metropolitan Road, Minhang District, Shanghai Code：201108